Work

Retrospective analysis of the efficacy and safety of disitamab vedotin (RC48) in Chinese patients with HER2-positive or HER2-low metastatic breast cancer.

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e13002

Authors: De Zeng, Wende Wang, Wenwu Xue, Minna Chen, Xiaofen Wen, Hui Lin

Institution: Cancer Hospital of Shantou University Medical College

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410819206

FWCI:

Cites:

Cited by:

Related to: 10